Navigation Links
Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD)
Date:5/15/2008

GREEN BAY, Wis., May 15 /PRNewswire/ -- Omega 3 fatty acids bound to phospholipids deserves to be further considered as a credible natural alternative and may have beneficial effect on impulsivity in ADHD patients, recent in vivo French study reveals. While several studies have reported beneficial effects of omega-3 in hyperactivity, French researchers have hypothesized that Vectomega(R) could have specific positive effects on impulse control.

These research findings have led to the initiation of two multi-center studies currently underway in France and Germany utilizing Vectomega(R) on hyperactive children. Vectomega(R), a natural whole food Omega 3 fatty acid bound to phospholipids and peptides, is the end result of a French governmental research project.

In 2001, the French government solicited researchers throughout France to investigate potential uses of omega 3 fatty acids and phospholipids. Vectomega(R) is an extract of marine phospholipids complexed with EPA and DHA from salmon heads, the result of the research work by three, world-renowned scientists in the field of phospholipids and essential fatty acids, Professor Michel Linder, Professor Jacques Fanni, and Professor Michel Parmentier. Professor Linder will visit the United States to present at the 99th Annual AOCS Meeting to be held in Seattle May 18-21, 2008.

Vectomega(R), distributed exclusively in the United States by EuroPharma Inc, is a whole food omega-3 EPA/DHA complex which includes phospholipids and marine peptides as they naturally occur in salmon. Molecularly different from other omega-3's on the market, Vectomega(R) is said to be up to 10 to 50 times more absorbable across cellular membranes, using Caco-2 analysis, than other EPA/DHA products.

Vectomega(R) is extracted using a patented enzymatic and pure water innovation that extracts naturally occurring marine phospholipids with the omega-3 fatty acids, EPA and DHA. The extraction is carried out in less than an hour in an inert atmosphere at a temperature lower than 60 degrees C. The omega 3 fatty acids, EPA and DHA can be extracted maintaining their position on the triglyceride chain using this patented process and keeping their natural proportions and composition. This patented innovation, called vectorization, uses a gentle, cold water and enzyme process avoiding heat, solvents, and chemical modifications that are utilized to process all other fish oils. This patented process provides an excellent advantage for the consumer, as the finished phospholipid complex is in tablet form, requiring only one tablet per day, with no regurgitation or fishy after-taste.

"Omega 3 oils containing EPA/DHA have become increasingly popular in response to the growing body of science that validates their numerous health benefits, including heart health and cognitive function," stated Terry Lemerond, president of EuroPharma. "Vectomega(R) surpasses all other EPA/DHA products in terms of bioavailability, absorption and efficacy. Much of the value is lost in fish oils currently on the market because they are highly refined, distilled and deodorized by the use of extraction processes that use high temperatures, solvents and chemical modifications. Vectomega(R) is the only whole food omega 3 complex that is extracted from salmon in a natural process," said Lemerond.

Prevalence estimates of ADHD diagnosis in US school-aged children is 7.4% (4.7 million children) according to the CDC website. The nutritional supplement omega 3 category is reported to be a $7 billion dollar market. The vast benefits of omega 3 supplementation are widely studied and recognized by the media and consumers.

EuroPharma, Inc. a Green Bay, Wisconsin-based nutritional supplement supplier offering a full line of dietary supplements to health food stores, doctors and natural pharmacies throughout the US. EuroPharma's president, Terry Lemerond has over 40 years of industry experience and product development expertise and is the recipient of the 2008 Natural Products Association Industry Champion Award. The Natural Products Association Industry Champion Award recognizes individuals who have made notable contributions to the natural products industry above and beyond commercial success. For more information on Vectomega(R) or EuroPharma(R), please contact Lisa Joski at Ljoski@EuroPharmaUSA.com, 920-406-6506, or visit http://www.EuroPharmaUSA.com.


'/>"/>
SOURCE EuroPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Pregnant Women Need Omega-3 to Boost Infant Development
2. Mayo Clinic Proceedings Contributors Highlight Research Findings About Cardiovascular Benefits Associated With Omega-3 Fatty Acids
3. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
4. Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
5. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
6. Mayo Clinic Study Identifies Potential Causes of Young-Onset Dementia
7. Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing
8. Michael J. Fox Foundation Announces $5.6-Million Award for Phase 2 Clinical Trial Studying Neuroprotective Potential of Inosine
9. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
10. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
11. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
Breaking Medicine News(10 mins):